<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611359</url>
  </required_header>
  <id_info>
    <org_study_id>2022-0698</org_study_id>
    <nct_id>NCT05611359</nct_id>
  </id_info>
  <brief_title>Surgery and Thermal Hepatic Ablation Combined With Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer</brief_title>
  <acronym>HOPE-1</acronym>
  <official_title>Resection of the Primary Pancreatic Tumour and Thermal Hepatic Ablation Combined With Chemotherapy vs. Chemotherapy in Hepatic Oligometastatic Pancreatic Cancer: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to compare the overall survival of thermal ablation&#xD;
      combined with chemotherapy and chemotherapy alone in the patients with liver oligometastasis&#xD;
      after pancreatic ductal adenocarcinoma (PDAC) surgery.&#xD;
&#xD;
      The main question it aims to answer is: whether thermal ablation combined with chemotherapy&#xD;
      can effectively prolong the overall survival in the patients with liver oligometastasis after&#xD;
      pancreatic ductal adenocarcinoma (PDAC) surgery.&#xD;
&#xD;
      The participants in the treatment group will receive systemic chemotherapy combined with&#xD;
      liver thermal ablation, while the participants in the control group will receive chemotherapy&#xD;
      alone. All participants will be followed up to evaluate the overall survival after treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      How to improve the overall survival in the patients with liver oligometastasis after&#xD;
      pancreatic ductal adenocarcinoma (PDAC) surgery is still a huge challenge in clinic.&#xD;
      Chemotherapy is still the first-line treatment for patients with liver oligometastasis after&#xD;
      PDAC resection. On the basis of chemotherapy, the clinical benefits of removing hepatic&#xD;
      oligometastasis by thermal ablation are still unclear. In this study, we will recruit&#xD;
      patients with liver oligometastasis after PDAC surgery to explore the effect of thermal&#xD;
      ablation combined with chemotherapy on the overall survival of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2023</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival time</measure>
    <time_frame>2 years</time_frame>
    <description>Time from thermal ablation to recurrence of liver lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related complications</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Relevant complication after thermal ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related mortality</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>2 years</time_frame>
    <description>Satisfaction questionnaire designed by investigator group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical cost</measure>
    <time_frame>2 years</time_frame>
    <description>Hospital expenditure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of serological examinationof liver function</measure>
    <time_frame>2 years</time_frame>
    <description>Serum concentration of tunmor biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Thermal Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, thermal ablation and chemotherapy are administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the patients with liver oligometastasis after pancreatic ductal adenocarcinoma (PDAC) surgery, chemotherapy is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal Ablation</intervention_name>
    <description>Thermal hepatic ablation Combined with Chemotherapy</description>
    <arm_group_label>Thermal Ablation</arm_group_label>
    <other_name>Thermal Ablation Combined with Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_label>Thermal Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (1) Age ≥ 18; (2) pancreatic ductal adenocarcinoma was confirmed by pathology; (3) The&#xD;
             patient's liver function was Child Pugh A or B ; (4) Karnofsky score ≥ 80; (5) There&#xD;
             is a safe puncture path under the guidance of ultrasound for liver oligometastatic&#xD;
             tumor; (6) Single diameter of liver oligometastatic tumor ≤ 5 cm, or ≤ 3 liver&#xD;
             oligometastatic tumors, each diameter ≤ 3 cm; (7) Platelet count&gt;40000/mm3; (8)&#xD;
             Thrombin time ratio&gt;40%; (9) Sign the Informed Consent of Clinical Trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Refuse to receive chemotherapy or thermal ablation; (2) &gt;3 liver metastases or&#xD;
             extrahepatic metastases (such as peritoneum, lung, bone or brain); (3) Single diameter&#xD;
             of liver oligometastatic tumor&gt;5 cm; (4) The patient has ascites, portal vein&#xD;
             thrombosis, or bile duct dilatation or stenosis; (5) Presence of another malignant&#xD;
             tumors; (6) Prior anti-tumor treatment (including radiotherapy, chemotherapy and&#xD;
             thermal ablation); (7) Presence of central nervous system abnormalities, mental&#xD;
             diseases, unstable angina, congestive heart failure, serious arrhythmia or other&#xD;
             serious diseases; (8) Use of anticoagulants maintenance treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pintong huang, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>the 2th affiliated hospital of zhejiang university school of medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>pintong huang, Doctor</last_name>
    <phone>0571-87783932</phone>
    <email>huangpintong@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>jianting yao, Doctor</last_name>
    <phone>0571-87783932</phone>
    <email>yaojianting@zju.edu.cn</email>
  </overall_contact_backup>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 6, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>Hepatic Metastasis</keyword>
  <keyword>Thermal Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

